Quantamental Technologies’s NovoCure NVCR Stock Holding History

Quantamental Technologies’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,051	Closed	-$66K	–	1726
2019 Q2	$66K	Buy	+1,051	New	+$53.3K	0.02%	817

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Quantamental Technologies's NVCR Position: Q3 2019 in Review

Quantamental Technologies sold out of NovoCure (NVCR) in Q3 2019, closing a stake of 1,051 shares — an estimated $66K sold.

Quantamental Technologies first reported a position in NVCR in Q2 2019 and held it in 1 quarter. The position peaked at $66K in Q2 2019. 240 funds tracked by Wall St. Rank hold NVCR as of Q3 2019.

Quantamental Technologies reported no remaining NovoCure position as of Q3 2019 after selling out during the quarter.
Quantamental Technologies sold 1,051 NovoCure shares in Q3 2019, an estimated $66K.
Quantamental Technologies first reported a position in NovoCure in Q2 2019 and held it in 1 quarter.
Quantamental Technologies's NovoCure position peaked at $66K in Q2 2019.
240 funds tracked by Wall St. Rank held NovoCure as of Q3 2019.

Based on Quantamental Technologies's 13F filing for Q3 2019, filed 8 Nov 2019.